Synapse - Genitourinary Oncology Service

Results (5692)

Evaluation of germline genetic testing criteria in early-onset kidney cancer

Meeting Abstract

Truong, H.; Sheikh, R.; Kotecha, R.; Kemel, Y.; Khurram, A.; Reisz, P.; Lenis, A. T.; Joseph, V.; Mandelker, D.; Lee, C. H.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO plus IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214

Meeting Abstract

Tannir, N. M.; Motzer, R. J.; Albiges, L.; Plimack, E. R.; George, S.; Powles, T.; Donskov, F.; Rini, B. I.; Grunwald, V.; Hammers, H. J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101

Meeting Abstract

Tomita, Y.; Motzer, R. J.; Choueiri, T. K.; Rini, B. I.; Miyake, H.; Oya, M.; Albiges, L.; Fujii, Y.; Umeyama, Y.; Wang, J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Enfortumab vedotin in FGFR3-mutated advanced urothelial carcinoma

Meeting Abstract

Teo, M. Y.; Ratna, N.; Regazzi, A. M.; Zimmerman, D. E.; McHugh, D. J.; Laccetti, A. L.; Xiao, H.; Lee, C. H.; Aggen, D. H.; Funt, S. A.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC)

Meeting Abstract

Rathkopf, D. E.; Chi, K. N.; Olmos, D.; Cheng, H. H.; Agarwal, N.; Graff, J. N.; Sandhu, S. K.; Hayreh, V.; Lopez-Gitlitz, A.; Francis, P. S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rathkopf, D. E.; Efstathiou, E.; Attard, G.; Flaig, T. W.; Franke, F. A.; Goodman, O. B.; Oudard, S.; Steuber, T.; Suzuki, H.; Wu, D.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Single cell RNA sequencing of upper tract urothelial carcinoma to reveal significant heterogeneity of the tumor and immune microenvironment

Meeting Abstract

Reisz, P.; Tracey, A.; Kuo, F.; Thomas, J.; Clinton, T. N.; Lenis, A. T.; Truong, H.; Nagar, K.; Bochner, B. H.; Pietzak, E. J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer

Meeting Abstract

Scher, H. I.; Armstrong, A. J.; Schonhoft, J. D.; Gill, A.; Zhao, J.; Barnett, E.; Carbone, E.; Lu, J.; Antonarakis, E. S.; Luo, J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma

Meeting Abstract

Powles, T.; Rosenberg, J. E.; Sonpavde, G.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Wu, C.; Campbell, M. S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rao, A.; Ryan, C. J.; VanderWeele, D. J.; Heller, G.; Lewis, L. D.; Watt, C.; Chen, R. C.; Grubb, R.; Hahn, O. M.; Beltran, H.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save